TY - JOUR
T1 - Profile of gantenerumab and its potential in the treatment of Alzheimer's disease
AU - Novakovic, Dijana
AU - Feligioni, Marco
AU - Scaccianoce, Sergio
AU - Caruso, Alessandra
AU - Piccinin, Sonia
AU - Schepisi, Chiara
AU - Errico, Francesco
AU - Mercuri, Nicola B.
AU - Nicoletti, Ferdinando
AU - Nisticò, Robert
PY - 2013/11/13
Y1 - 2013/11/13
N2 - Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect about 63 million people by 2030, and 114 million by 2050, worldwide. Current Alzheimer's disease medications may ease symptoms for a time but are not capable of slowing down disease progression. Indeed, all currently available therapies, such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine), are primarily considered symptomatic therapies, although recent data also suggest possible disease-modifying effects. Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease. Here, we present an overview of gantenerumab ranging from preclinical studies to human clinical trials.
AB - Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect about 63 million people by 2030, and 114 million by 2050, worldwide. Current Alzheimer's disease medications may ease symptoms for a time but are not capable of slowing down disease progression. Indeed, all currently available therapies, such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine), are primarily considered symptomatic therapies, although recent data also suggest possible disease-modifying effects. Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease. Here, we present an overview of gantenerumab ranging from preclinical studies to human clinical trials.
KW - Alzheimer's disease
KW - Amyloid-β
KW - Clinical trials
KW - Gantenerumab
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=84887763795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887763795&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S53401
DO - 10.2147/DDDT.S53401
M3 - Article
C2 - 24255592
AN - SCOPUS:84887763795
VL - 7
SP - 1359
EP - 1364
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
SN - 1177-8881
ER -